{"id":"lucentis-every-12-weeks","safety":{"commonSideEffects":[{"rate":"25–30","effect":"Conjunctival hemorrhage"},{"rate":"5–10","effect":"Eye pain"},{"rate":"5–10","effect":"Floaters"},{"rate":"5–10","effect":"Intraocular pressure elevation"},{"rate":"<1","effect":"Endophthalmitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds and neutralizes all active forms of VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF-A signaling, it prevents endothelial cell proliferation and reduces retinal edema, thereby slowing or halting vision loss in conditions characterized by abnormal retinal vasculature.","oneSentence":"Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:39.760Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Macular edema following retinal vein occlusion"},{"name":"Diabetic macular edema"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT03683251","phase":"PHASE3","title":"Extension Study for the Port Delivery System With Ranibizumab (Portal)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-09-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1000},{"nctId":"NCT07389577","phase":"PHASE3","title":"A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2022-03-01","conditions":"Wet Age-related Macular Degeneration","enrollment":443},{"nctId":"NCT03161652","phase":"PHASE2","title":"Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema","status":"RECRUITING","sponsor":"Carmen Clapp","startDate":"2017-05-24","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":120},{"nctId":"NCT05151731","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-31","conditions":"Diabetic Macular Edema","enrollment":394},{"nctId":"NCT05151744","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-17","conditions":"Diabetic Macular Edema","enrollment":187},{"nctId":"NCT03927690","phase":"PHASE2","title":"Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-24","conditions":"Diabetic Macular Edema","enrollment":91},{"nctId":"NCT01610557","phase":"PHASE2","title":"Ranibizumab and Bevacizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2012-05","conditions":"Diabetic Macular Edema","enrollment":56},{"nctId":"NCT03038880","phase":"PHASE2","title":"Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-27","conditions":"Neovascularization, Choroidal, Macular Degeneration, Age-Related","enrollment":76},{"nctId":"NCT01934556","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Palmetto Retina Center, LLC","startDate":"2013-11","conditions":"Diabetic Macular Edema","enrollment":150},{"nctId":"NCT02484690","phase":"PHASE2","title":"A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-11","conditions":"Choroidal Neovascularization","enrollment":273},{"nctId":"NCT01982435","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Ranibizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Justis Ehlers","startDate":"2014-06-24","conditions":"Diabetic Macular Edema","enrollment":27},{"nctId":"NCT03423823","phase":"PHASE2","title":"Ziv-aflibercept Efficacy in Better Regulating AMD","status":"COMPLETED","sponsor":"Kapil Kapoor","startDate":"2017-07-07","conditions":"Wet Macular Degeneration, Wet Age-related Macular Degeneration","enrollment":62},{"nctId":"NCT02462486","phase":"PHASE3","title":"Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-06-25","conditions":"Macular Degeneration","enrollment":949},{"nctId":"NCT02462928","phase":"PHASE3","title":"A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-06-25","conditions":"Macular Degeneration","enrollment":939},{"nctId":"NCT01397409","phase":"PHASE2","title":"Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-09-01","conditions":"Age-related Macular Degeneration","enrollment":271},{"nctId":"NCT01945866","phase":"PHASE2","title":"Phase II Combination Steroid and Anti-VEGF for Persistent DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2014-02","conditions":"Diabetic Macular Edema","enrollment":129},{"nctId":"NCT02530918","phase":"PHASE1","title":"Study of DS-7080a for the Treatment of Macular Degeneration","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-07","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":56},{"nctId":"NCT01863199","phase":"PHASE4","title":"Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Retinal Consultants of Arizona","startDate":"2013-05","conditions":"Neovascular Age Related Macular Degeneration","enrollment":60},{"nctId":"NCT02181504","phase":"PHASE2","title":"A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-09","conditions":"Macular Degeneration","enrollment":25},{"nctId":"NCT01025232","phase":"PHASE1, PHASE2","title":"A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)","status":"TERMINATED","sponsor":"David M. Brown, M.D.","startDate":"2009-12","conditions":"Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration","enrollment":88},{"nctId":"NCT02181517","phase":"PHASE2","title":"A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-07","conditions":"Macular Degeneration","enrollment":25},{"nctId":"NCT02186119","phase":"PHASE2","title":"A Study of Abicipar Pegol in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-07","conditions":"Macular Edema","enrollment":151},{"nctId":"NCT00557791","phase":"PHASE3","title":"Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)","status":"WITHDRAWN","sponsor":"OPKO Health, Inc.","startDate":"2009-11","conditions":"Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT00637377","phase":"PHASE3","title":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Macular Degeneration","enrollment":1240},{"nctId":"NCT00499590","phase":"PHASE3","title":"Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD","status":"TERMINATED","sponsor":"OPKO Health, Inc.","startDate":"2007-08","conditions":"Macular Degeneration","enrollment":338},{"nctId":"NCT00509795","phase":"PHASE3","title":"Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2007-08","conditions":"Macular Degeneration","enrollment":1217},{"nctId":"NCT00713518","phase":"PHASE2","title":"Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).","status":"COMPLETED","sponsor":"Quark Pharmaceuticals","startDate":"2009-11","conditions":"Age Related Macular Degeneration","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lucentis every 12 weeks","genericName":"Lucentis every 12 weeks","companyName":"Retinal Consultants of Arizona","companyId":"retinal-consultants-of-arizona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}